Appeal 2007-2516
Application 10/302,553
3. “[L]ung surfactant compositions comprise phospholipids and . . . can
additionally contain lung surfactant proteins” (Hafner ‘970, col. 3, ll. 42-44).
4. The lung surfactant compositions can also contain calcium to set a
favorable viscosity (Hafner ‘970, col. 3, ll. 46-48).
5. Commercially available lung surfactants include “Curosurf® . . . , a
highly purified natural surfactant from homogenized pigs’ lungs, Survanta®
. . . and Alveofact® . . . , both extracts of bovine lungs, and also Exosurf® . .
. , a synthetic phospholipid with auxiliaries” (Hafner ‘970, col. 3, ll. 48-55).
6. Hafner ‘970 describes therapeutic compositions which comprise
dipalmitoylphosphatidylcholine, which is a phospholipid (Hafner ‘970, cols.
4-5, Examples 1-4), or lung surfactant purified from bovine lungs (Hafner’
970, col. 5, ll. 40-45, Example 5).
7. The composition can be a powder (Hafner ‘970, col. 5, ll. 4-6) which is
administered by inhalation (Hafner ‘970, col. 4, ll. 25-29).
8. Using an animal model for ARDS, Hafner ‘970 shows that administration
of lung surfactant as powder improves lung function, leading to a desired
rise in the PaO2 (Hafner ‘970, col. 6, ll. 53-55; cols. 7-8, Tables 1 and 2;
Answer 5-6).
9. Hafner ‘970 also shows that increasing surfactant dosage results in a rise
in PaO2. See Hafner ‘970, Tables 1 and 2, showing the effect of lung
surfactant dosages of 25 mg/kg and 100 mg/kg.
Alliance
10. It is stated in the instant Specification that “[p]articularly preferred
embodiments of the invention incorporate spray dried, hollow and porous
particulate compositions as disclosed in WO 99/16419 [Alliance]”
(Specification 7: 17-18).
4
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 Next
Last modified: September 9, 2013